FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT BY AND AMONG IMMUNOGEN, INC., BIOTECHNOLOGY VENTURE PARTNERS, L.P., BIOTECHNOLOGY VALUE FUND, L.P., BIOTECHNOLOGY VALUE FUND, LTD. AND INVESTMENT 10, L.L.C.Stock Purchase Agreement • December 7th, 1998 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
EXHIBIT 1.1 4,000,000 SHARES IMMUNOGEN, INC. COMMON STOCK $.01 PAR VALUE UNDERWRITING AGREEMENT ----------------------Underwriting Agreement • October 27th, 2000 • Immunogen Inc • Pharmaceutical preparations • New York
1 EXHIBIT 10.48 Immunogen, Inc. has omitted from this Exhibit 10.48 portions of the Agreement for which Immunogen, Inc. has requested confidential treatment from the Securities and Exchange Commission. The portions of the Agreement for which...License Agreement • September 29th, 1998 • Immunogen Inc • Pharmaceutical preparations
LEASELease • September 26th, 1997 • Immunogen Inc • Pharmaceutical preparations
AMENDMENT TO LEASE Agreement made this 31st day of August, 1995 between Massachusetts Institute of Technology, Treasurer's Office, Suite 200, 238 Main Street, Cambridge, MA 02142 ("Lessor") and ImmunoGen, Inc., 128 Sidney Street, Cambridge, MA 02139...Lease Agreement • September 28th, 1995 • Immunogen Inc • Pharmaceutical preparations
BY AND AMONGStock Purchase Agreement • February 17th, 1998 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
ImmunoGen, Inc. 9,000,000 Shares of Common Stock, par value $0.01 per share Underwriting AgreementImmunogen Inc • May 7th, 2010 • Pharmaceutical preparations • New York
ImmunoGen, Inc., a Massachusetts corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 9,000,000 shares of Common Stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,350,000 shares of Common Stock, par value $0.01 per share, of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock, par value $0.01 per share, of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
2- 3 (i) Neither the giving of this consent nor anything contained herein shall be construed to modify, waive, impair or affect any of the covenants, agreements, terms, provisions, obligations or conditions contained in the Lease (except as may herein...Master Lease Agreement • February 15th, 1996 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
AND IMMUNOGEN, INCConfidential Treatment • September 27th, 2000 • Immunogen Inc • Pharmaceutical preparations • New York
SUBLEASE Dated: August 31 , 1995Immunogen Inc • September 28th, 1995 • Pharmaceutical preparations • Massachusetts
ImmunoGen, Inc. 26,000,000 Shares of Common Stock, par value $.01 per share Underwriting AgreementUnderwriting Agreement • May 5th, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations • New York
ImmunoGen, Inc., a Massachusetts corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 26,000,000 shares (the “Firm Shares”) of common stock, par value $.01 per share, of the Company (the “Common Stock”) and, at the option of the Underwriters, up to an additional 3,900,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
and IMMUNOGEN, INC. 2 LICENSE AGREEMENTLicense Agreement • February 16th, 1999 • Immunogen Inc • Pharmaceutical preparations • Pennsylvania
EXHIBIT 10.34 CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (this "AGREEMENT"), dated as of October 16, 1996, between Southbrook International Investments, Ltd., a corporation organized and existing under the laws of the British Virgin Islands (the...Convertible Preferred Stock Purchase Agreement • November 8th, 1996 • Immunogen Inc • Pharmaceutical preparations • New York
1 Exhibit 10.1 Morphosys - Immunogen Collaboration and License Agreement Execution Copy COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement ("Agreement") is made effective as of September 29, 2000 ("Effective Date") by and...Collaboration and License Agreement • October 10th, 2000 • Immunogen Inc • Pharmaceutical preparations • Delaware
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • December 18th, 2020 • ImmunoGen, Inc. • Pharmaceutical preparations • New York
ImmunoGen, Inc., a Massachusetts corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.01 per share (the “Common Shares”), having an aggregate offering price of up to $150,000,000 on the terms set forth in this agreement (this “Agreement”).
WITNESSETH:License Agreement • September 26th, 1997 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
1 Exhibit 10.52 HEADS OF AGREEMENT: IMMUNOGEN /GENENTECH COLLABORATIVE AGREEMENT A. EFFECTIVE DATE: The effective date of this Heads of Agreement ("HEADS OF AGREEMENT") shall be as of May 2, 2000 (the "EFFECTIVE DATE"). B. PARTIES: The parties to this...Heads of Agreement • September 27th, 2000 • Immunogen Inc • Pharmaceutical preparations
1 ASSIGNMENT OF LEASE THIS ASSIGNMENT OF LEASE (this "Agreement"), dated as of January 1, 1996, by and between IMMUNOGEN, INC. ("Tenant"), a Massachusetts corporation, and ORAVAX, INC. ("Assignee"), a Delaware corporation. WHEREAS, by a lease (the...Assignment of Lease • February 15th, 1996 • Immunogen Inc • Pharmaceutical preparations
UNDERWRITING AGREEMENTUnderwriting Agreement • June 18th, 2009 • Immunogen Inc • Pharmaceutical preparations • New York
ImmunoGen, Inc., a Massachusetts corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you, Oppenheimer & Co. Inc., and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 5,000,000 shares (the “Firm Shares”) of the Company’s common stock, $.01 par value per share (the “Common Stock”). In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 750,000 shares (the “Company Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”
1 EXHIBIT 99.1 STOCKHOLDERS' AGREEMENT This Agreement made as of this 11th day of January, 1993, by and among ImmunoGen, Inc., a Massachusetts corporation with its principal place of business at 148 Sidney Street, Cambridge, Massachusetts 02139...Stockholders' Agreement • March 20th, 1998 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
IMMUNOGEN, INC. COMMON STOCK SALES AGREEMENTCommon Stock • March 3rd, 2017 • Immunogen Inc • Pharmaceutical preparations • New York
CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • November 2nd, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement is entered into as of the 18th day of September, 2023 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Lauren White (the “Executive”).
ImmunoGen, Inc. 11,636,364 Shares of Common Stock, par value $0.01 per share Pre-Funded Warrants to Purchase 27,363,636 Shares of Common Stock Underwriting AgreementLetter Agreement • December 3rd, 2021 • ImmunoGen, Inc. • Pharmaceutical preparations • New York
ImmunoGen, Inc., a Massachusetts corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,636,364 shares (the “Underwritten Shares”) of common stock, par value $0.01 per share, of the Company (the “Common Stock”), pre-funded warrants to purchase an aggregate of 27,363,636 shares of Common Stock in the form attached as Exhibit A (the “Warrants”) and, at the option of the Underwriters, up to an additional 5,850,000 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Warrants are herein referred to as the “Underwritten Securities.” The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock issuable upon exercise of the Warrants are herein referred to as the “Warrant Shares.” The Shares and Warrants are herein referred to as the “Securities.” The sha
EXHIBIT 10.35 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "AGREEMENT") is made and entered into as of October 16, 1996, by and among ImmunoGen, Inc., a Massachusetts corporation (the "COMPANY"), and Southbrook International...Registration Rights Agreement • November 8th, 1996 • Immunogen Inc • Pharmaceutical preparations • New York
1 EXHIBIT 10.2 IMMUNOGEN, INC. REGISTRATION AGREEMENT THIS AGREEMENT, is made as of December 9, 1997 among ImmunoGen, Inc., a Massachusetts Corporation (the "Company"), Biotechnology Venture Partners, L.P. ("BVP"), a _____________ limited partnership,...Registration Agreement • February 17th, 1998 • Immunogen Inc • Pharmaceutical preparations
WITNESSETH:Research Collaboration Agreement • September 26th, 1997 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
SEVERANCE AGREEMENTSeverance Agreement • February 8th, 2011 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Agreement is entered into as of the 1st day of December, 2010 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Craig Barrows (the “Executive”).
IMMUNOGEN, INC. NON-QUALIFIED STOCK OPTION AGREEMENTNon-Qualified Stock Option Agreement • November 15th, 2006 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
WHEREAS, the Company desires to grant to the Participant an Option to purchase shares of its common stock, $.01 par value per share (the “Shares”), under and for the purposes set forth in the Company’s 2006 Employee, Director and Consultant Equity Incentive Plan (the “Plan”);
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omissions. LOAN AGREEMENT Dated as...Loan Agreement • April 28th, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations
THIS LOAN AGREEMENT (this “Agreement”), dated as of April 6, 2023 (the “Effective Date”) by and among IMMUNOGEN, INC., a Massachusetts corporation (as “Borrower” and a Credit Party), the Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”), and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows:
IMMUNOGEN, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • November 15th, 2006 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
AGREEMENT made as of the day of 200 , between ImmunoGen, Inc. (the “Company”), a Massachusetts corporation, and , an employee of the Company (the “Employee”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 23rd, 2008 • Immunogen Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 20, 2008, between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Ziff Asset Management, L.P., a Delaware limited partnership (the “Purchaser”).
RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • August 4th, 2017 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
AGREEMENT made as of the _______ day of ___________________, 201__ (the “Grant Date”), between ImmunoGen, Inc. (the “Company”), a Massachusetts corporation, and ________________________ (the “Participant”).
2. 3 (b) Provided that ImmunoGen has delivered to SB the Additional Shares Sale Notice in compliance with Subsection 1.4(a) above, and subject to Section 1.8 below, on the Second Closing Date (as defined in Section 1.5), ImmunoGen shall issue and sell...Stock Purchase Agreement • February 16th, 1999 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
PURCHASE AGREEMENT IMMUNOGEN, INC. Purchase AgreementPurchase Agreement • June 20th, 2016 • Immunogen Inc • Pharmaceutical preparations • New York
ImmunoGen, Inc., a Massachusetts corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representative (the “Representative”), $100,000,000 principal amount of its 4.50% Convertible Senior Notes due 2021 (the “Underwritten Securities”) and, at the option of the Initial Purchasers, up to an additional $15,000,000 principal amount of its 4.50% Convertible Senior Notes due 2021 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 4.50% Convertible Senior Notes due 2021 granted to the Initial Purchasers in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into shares (the “Underlying Securities”) of common stock of the Company, par value $0.01 per share (the “Common Stock”). The Securities wi
Exchange AgreementExchange Agreement • September 26th, 2017 • Immunogen Inc • Pharmaceutical preparations • New York
This Exchange Agreement and the Terms and Conditions for Exchange of Securities, dated September [ ], 2017, attached hereto as Exhibit A (the “Terms and Conditions” and, together with this Exchange Agreement, the “Agreement”) is made as of the date hereof between the Company and the Investor.
